PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

Getty Images

News | Radiopharmaceuticals and Tracers | September 17, 2021
September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and...
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
The use of positron emission tomography (PET) imaging in preclinical oncology investigations has shown the ability to...
Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1 platform. 
News | PET Imaging | September 13, 2021
September 13, 2021 — Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and...
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging...
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master...
Wisconsin-based company will help secure U.S. supply of Mo-99 used in 40,000 medical procedures daily, promote nuclear nonproliferation
News | Nuclear Imaging | August 27, 2021
August 27, 2021 — The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) issued two...
CDI Quality Institute, a non-profit affiliate of RAYUS Radiology, one of the nation's leading national subspecialty providers for advanced diagnostic and interventional radiology services, once again qualified as a Provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program with the Centers for Medicare & Medicaid Services (CMS)
News | Radiology Business | August 23, 2021
August 24, 2021 — CDI Quality Institute, a non-profit affiliate of RAYUS Radiology, one of the nation's leading...
#coronavirus #COVID19 #pandemic #RSNA21 will require all attendees and exhibitors to show proof of #vaccination and wear a #mask

Getty Images

News | RSNA | August 12, 2021
August 12, 2021 — RSNA 2021 will require proof of COVID-19 vaccination from all in-person attendees and exhibitors at...
Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

News | PET Imaging | August 06, 2021
August 6, 2021 — A multidisciplinary team has demonstrated the production, purification, and potential application of...
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are expected to continue to incorporate the highest clinical performance of PET as well...
Positrigo reports completion of the ExploreBPET clinical study, using the novel investigational medical device BPET for imaging of the human brain
News | PET Imaging | August 03, 2021
August 3, 2021 — Positrigo, a company developing nuclear medical imaging devices that advance functional imaging,...

Image courtesy of Vital Images

News | Molecular Imaging | August 02, 2021
August 2, 2021 — The global molecular imaging market was evaluated at $4.199 billion for the year 2019 growing at a...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly...

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
July 16, 2021 — Positrigo, a company developing nuclear medical imaging devices to advance functional imaging, today...
Humana’s new draft Fusion policy outlines coverage determinations for myocardial assessment and the use of PET/CT and SPECT/CT for certain neurologic indications. ASNC has submitted additional feedback on the draft policy.
News | PET-CT | July 13, 2021
July 13, 2021 — In a recent blog, the American Society of Nuclear Cardiology (ASNC) reported that Humana, one of the...
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.

Human imaging examples of performance of uEXPLORER total-body PET scanner. (A) Axial slice from 18F-fluciclovine PET image (right), with corresponding fused image (middle) and CT image (left), of 68-y-old patient with castration-resistant metastatic prostate cancer, demonstrating clear visualization of 18F-flucicovine accumulation within 2.5-mm-diameter pulmonary nodule. (B) Maximum-intensity projection of representative clinical oncology 18F-FDG PET scan reconstructed with 20-, 5-, and 2.5-min durations, of 59-y-old patient with lung cancer. Images show primary tumor in left lower lobe of lung (dashed circle), with multiple variable-sized (0.8-6 cm) hilar, mediastinal, and lower esophageal nodal metastases (arrows) and ~1-cm 18FFDG-avid left adrenal nodule (arrowhead), which is visualized for all scan durations. Image created by Y. Abdelhafez and B.A. Spencer, EXPLORER Molecular Imaging Center, UC Davis, Sacramento, CA

News | PET Imaging | July 10, 2021
July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high...
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images

News | PET Imaging | July 08, 2021
July 8, 2021 — Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated...
The RefleXion X1 is the world’s first biology-guided radiotherapy (BgRT) machine that’s expected to improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.
News | Radiation Therapy | June 29, 2021
June 29, 2021 —  UPMC Hillman Cancer Center will be the first cancer center in the eastern United States, and one of...
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021
June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate...